ClinicalTrials.gg
RecruitingNCT06209359MsDR Aim 3Updated May 22, 2026

Mechanisms of Diuretic Resistance in Heart Failure, Aim 3

A Phase 1 interventional study of Ammonium Chloride and Placebo in Heart Failure and Diuretic Resistance, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Yale University · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Heart Failure by Yale University — 9 open to participants now, 12 under way, none of them phase 3. Heart Failure · Yale University.

Planned enrollment
18th of 27
50 · median 72
Started
2024
the only one that year
Phase 1
8 of 33
3 open now
Primary completion
2029-03
later than 10 of 11 live
Registered
27th of 33
by date

Among the 33 studies in Heart Failure by Yale University, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 1, reaches primary completion later than 10 of the 11 other live ones, and was the 27th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 33 studies in Heart Failure by Yale University are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Heart Failure by Yale University, or all of them as a file.
02

Study summary

Randomized double-blind placebo-controlled crossover study design

Read the detailed description

Briefly, the protocol will begin with pre-study determination of diuretic response at the screening visit via administration of 10 mg IV bumetanide and measuring peak FENa. Participants may proceed to the subsequent study procedures. Participants will begin a study diet provided by the metabolic kitchen five days prior to Day 0. Beginning on day 0, participants will take either NH4Cl or placebo 75mmol twice daily. On day 1, the participant will return to study site and receives the first dose of their twice daily study medication as well as their regular loop diuretic dose given as IV bumetanide, followed by completion of the biospecimen collection protocol and a 24-hour urine collection. On day 2, participants will receive a full 150mmol dose at Hr-2 (75 mmol if pH\<7.3-7.25, no NH4Cl if pH\<7.25). 2 hours after the IV bumetanide is given, 100mmol of sodium bicarbonate in 750ml of 5% dextrose will be administered to participants that received NH4Cl or 750 ml of lactated Ringer's solution to participants that received placebo (provided blinded by the investigational pharmacy).

After this visit, a washout period will be conducted before the above procedures are repeated with the alternate study medication. The washout period will be a minimum of 10 days and a maximum of 28 days. Five days prior to the end of the washout period, the participant will resume the study diet until the end of the study on day 18. On day 16, the participant will be crossed over to the alternate therapy (NH4Cl or placebo). On day 17, the participant will complete the same procedures as day 1 of the first arm. On day 18, the participant will complete the same procedures as day 2 of the first arm.

The administration of Bendroflumethiazide will occur under a separate ancillary protocol

03

Conditions studied

  • Heart Failure
  • Diuretic Resistance

Keywords

  • Diuretic
  • Cardiomyopathy
  • Diuretic Resistance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of heart failure
  • No plan for titration/change of heart failure medical or device therapies during the study period.
  • Absence of non-elective hospitalizations in the previous 2 months.
  • At optimal volume status by symptoms, exam, and dry weight.
  • Serum potassium ≤ 5.0 mmol/L
  • Serum sodium ≥ 130 milliequivalents/ liter (mEq/L)
  • ≥8 g/dL
  • Age >18 years
  • Objective evidence of diuretic resistance to a 10mg bumetanide challenge (screening visit may occur under this protocol or HIC2000032328 or HIC2000034315) defined as:

    • FENa \<10% and total sodium output \<150mmol
    • And at least one of the following criteria:

      • Chronic home furosemide dose greater than or equal to 80mg furosemide equivalents
      • \< 60ml/min
      • Serum chloride \<100mmol/L
      • FENa \<5% and total sodium output \<75mmol on the 2 hour

Exclusion criteria

Exclusion Criteria:

  • (GFR) \<20 ml/min/1.73m2
  • Use of any non-loop type diuretic in the last 7 days with the exclusion of low dose aldosterone antagonist (e.g., spironolactone ≤50 mg)
  • History of flash pulmonary edema or a "brittle" volume sensitive HF phenotype such as amyloid cardiomyopathy
  • \< 8 g/dL
  • Pregnant or breastfeeding
  • Cirrhosis or known liver disease
  • History of metabolic or respiratory acidosis within 30 days
  • Use of metformin, acetazolamide, or any other agent that could predispose to acidosis
  • Patients who are on metformin may be enrolled if their metformin can be safely discontinued for the randomized treatment periods in each arm. Any participants who have consistently elevated blood glucose readings > 200 mg/dL while inpatient will not be enrolled.
  • Serum bicarbonate level \<24mmol/L at screening visit
  • Venous potential of hydrogen(pH) \<7.35 at screening visit
  • Inability to give written or comply with study protocol or follow-up visits
  • On Lithium therapy
  • On pimozide or thioridazine
  • Diagnosis of liver failure
  • or allergy to sulfonamides
  • Any contraindication to thiazide diuretic or allergy to thiazide or bendroflumethiazide
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Ammonium chloride

    Participants will be randomized to ammonium chloride vs placebo. On Day 0 and 1, the participant will take ammonium chloride or placebo 75 mmol twice daily. On Day 2, the participant will take ammonium chloride 150 mmol or placebo once

    Drug: Ammonium Chloride

  • Placebo comparator
    Placebo

    Participants will be randomized to ammonium chloride vs placebo. On Day 0 and 1, the participant will take ammonium chloride or placebo 75 mmol twice daily. On Day 2, the participant will take ammonium chloride 150 mmol or placebo once

    Drug: Placebo

Interventions

  • DrugAmmonium Chloride

    Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.

  • DrugPlacebo

    Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.

06

What researchers measure

Primary outcomes

  1. Change of distal sodium reabsorption(ADRNa) between NH4Cl vs. placebo study visits

    Comparison of ADRNa between NH4Cl vs. placebo during study visits using fractional excretion of lithium and fractional excretion of sodium to calculate the ADRNa.

    Time frame: Day 0 vs Day 1

  2. Change of distal sodium reabsorption(ADRNa) between NH4Cl vs. placebo study visits

    Comparison of ADRNa between NH4Cl vs. placebo during study visits using fractional excretion of lithium and fractional excretion of sodium to calculate the ADRNa.

    Time frame: Day 2 vs Day 18

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Mar 2029, 55 months after the start.

Of 54 non-industry phase 1 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 55 months is above that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Jan 17, 2024
StartActual
Jul 24, 2024
Primary completionEst.
Mar 1, 2029
CompletionEst.
Mar 1, 2029
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06209359
Lead sponsor
Yale University
Responsible party
Jeffrey Testani (Associate Professor of Medicine, Yale University) — Principal investigator
First posted
Jan 17, 2024
Start date
Jul 24, 2024
Primary completion
Mar 1, 2029 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
May 22, 2026

Study contacts

Veena Rao, PHD
Contact
veena.s.rao@yale.edu
2037373571
Jeffrey Testani, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion